Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enoxaparin Sodium 40 versus Clexane after high-risk knee surgery
2014-001954-40Phase 3Completed
- Sponsor
- Sciencepharma
- Start
- Aug 2014
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of enoxaparin in venous thromboembolism (VTE) (2 arms), sponsored by Sciencepharma. Primary endpoint: Incidence of patients with any bleeding events. Started Aug 2014; status: completed.
02
Drugs
enoxaparin
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on 2014-001954-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001954-40.